Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Pradigastat
Cat. No.:
OB0425LY-233
Appearance:
Solid
Purity:
98.88%
Identity:
Confirmed by LC-MS.
Size:
Add to basket
Product Overview
Description:
Pradigastat is an enzyme inhibitor with metabolic regulation and blood glucose lowering effects.
Synonyms:
LCQ-908; 956136-95-1; LCQ908; 2-((1R,4R)-4-(4-(5-((6-(Trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid; 2-{4-[4-(5-{[6-(Trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid
CAS No.:
956136-95-1
Compound CID:
53387035
Formula:
C25H24F3N3O2
Formula Weight:
455.47
Specification
Target:
Acyltransferase; BCRP; OAT
Pathway:
Metabolic enzyme/Protease; Membrane transporter/Ion channel
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
Pradigastat is mainly for drug development related to type 2 diabetes.
